FDA Further Expands Approval of HCV Combo Drug Mavyret FDA Further Expands Approval of HCV Combo Drug Mavyret

Mavyret is the first 8-week treatment approved for all treatment-naive adult and certain pediatric patients with any hepatitis C virus genotype, both without cirrhosis and with compensated cirrhosis.FDA Approvals
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Gastroenterology News Alert Source Type: news